Collectively, these data illustrate that the convergence of activated Wnt, MAPK, and TGFβ/ALK5 signalling drives mitogenic and survival pathways that can be targeted therapeutically to slow the progression of intestinal tumours with aggressive behavioural traits. The gene discussed is TGFBR1; the disease is intestinal neoplasm.